科前生物(688526) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 204,929,240.40, representing a decrease of 26.68% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2024 was CNY 87,228,395.78, down 35.64% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 76,157,757.92, a decline of 40.56% compared to the previous year[4] - The net cash flow from operating activities for Q1 2024 was CNY 133,086,579.74, reflecting a decrease of 25.28% year-over-year[4] - The basic earnings per share for Q1 2024 was CNY 0.18, down 37.93% from the same period last year[4] - Total operating revenue for Q1 2024 was CNY 204,929,240.40, a decrease of 26.7% compared to CNY 279,514,834.18 in Q1 2023[47] - Net profit for Q1 2024 was CNY 87,075,680.66, a decline of 35.7% from CNY 135,431,910.74 in Q1 2023[49] - Earnings per share for Q1 2024 were CNY 0.18, compared to CNY 0.29 in Q1 2023, indicating a decrease of 37.9%[50] - The company reported a total comprehensive income of CNY 90,397,978.13 for Q1 2024, compared to CNY 135,431,910.74 in Q1 2023, reflecting a decrease of 33.2%[50] Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,886, a decrease from the previous period[20] - The largest shareholder, Wuhan Huazhong Agricultural University Asset Management Co., Ltd., holds 16.73% of the shares[20] Assets and Liabilities - The total assets of the company as of the end of the reporting period were CNY 4,618,384,078.67, a slight decrease from CNY 4,671,249,471.01 in the previous period[26] - The company's fixed assets amounted to CNY 775,940,117.70, down from CNY 799,006,067.68 in the previous period[26] - Total liabilities decreased to ¥714,705,064.38 from ¥833,592,147.28 year-over-year[46] - The company’s total equity remained stable at ¥466,168,016.00[46] - Total assets at the end of the period were CNY 4,618,384,078.67, a decrease of 1.13% from the previous year[59] Cash Flow - Cash and cash equivalents increased to ¥800,292,120.31 from ¥581,740,744.51 year-over-year[43] - The net cash flow from operating activities was CNY 133,086,579.74, a decrease from CNY 178,103,336.61 in the previous period[53] - Total cash inflow from investment activities was CNY 446,189,764.61, compared to CNY 284,912,353.77 in the prior period[53] - The net cash flow from financing activities was negative at CNY -127,421,577.91, contrasting with a positive CNY 112,981,269.22 in the previous period[54] - The net increase in cash and cash equivalents was CNY 231,090,103.56, compared to CNY 270,276,842.01 in the prior period[54] - The total cash outflow from investment activities was CNY 220,764,662.94, down from CNY 305,720,117.59 in the prior period[53] Research and Development - The company obtained 44 new veterinary drug registration certificates, including 31 in collaboration with Huazhong Agricultural University and 12 with third-party partners[40] - Research and development expenses totaled CNY 19,840,800.13, representing 9.68% of operating revenue, an increase of 1.99 percentage points[59] - The company is focusing on laboratory research for multiple vaccines, including the live vaccine for porcine mycoplasma pneumonia, which generated approximately $538,276 in revenue[12] - Future outlook includes continued investment in research and development to enhance product offerings and address emerging market needs[4] Product Development and Market Expansion - The company is actively developing new products, including a recombinant canine parvovirus vaccine, which generated approximately $393,517 in revenue[22] - The company is expanding its market presence with clinical trials for rabies inactivated vaccines, which generated approximately $792,755 in revenue[23] - The company is exploring new strategies for market expansion through the development of innovative vaccine solutions, particularly in the swine and poultry sectors[4] - The total revenue from new veterinary drug registrations reached approximately $1.4 million across various products, indicating a strong pipeline[4] Challenges and Losses - The net profit attributable to shareholders decreased by 35.64% due to downstream supply chain pressures and a decline in operating revenue[37] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 40.56%, primarily driven by reduced operating revenue[37] - The diluted earnings per share also decreased by 37.93% due to the decline in operating revenue[37] - The company reported a loss of approximately $2.55 million from the study of Mycoplasma bovis competitive ELISA antibody test kits[9] - The indirect ELISA antibody test kit for African swine fever virus showed a loss of approximately $1.31 million, indicating challenges in this product line[18]